Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.

At Winter Poster Session, Eager Student Interns Present Research for the First Time

Butterflies in the stomach, a cold sweat, a feeling of dread: most of us know and fear the nervousness that accompanies public speaking. It was a pleasant surprise, therefore, to see apparently fearless Werner H. Kirsten student interns speak at NCI at Frederick’s WHK Student Intern Program Winter Poster Session. The event gave the dozen or so high school students a chance to present their hard-won research to NCI at Frederick staff. For many, it was their first time speaking about their projects in public.

“Something Just Clicked”: Partnership Pushes New Class of Cancer Drug Toward Human Trials

Serguei Kozlov, Ph.D., doesn’t recall if it was he who first contacted clinician Udo Rudloff, M.D., Ph.D., or Rudloff who contacted him. He just knows that their resulting two-year collaboration, which recently moved a first-in-class drug for metastatic cancer toward clinical trials, is one of the best he’s ever had.

Meet Leonard Freedman, Frederick National Laboratory’s New Chief Science Officer

For Leonard Freedman, Ph.D., a lifetime in the sciences began serendipitously at Kalamazoo College, a small liberal arts school in Michigan. Freedman, who is Frederick National Laboratory’s new chief science officer, was drawn to the college’s strong science and premedical programs. However, he says many other subjects were equally attractive during his studies.

NICBR Winter Symposium Focuses on Novel Therapeutics Research

Attendees packed the Building 549 Conference Center for the National Interagency Confederation for Biological Research (NICBR) Winter Symposium, the latest in a series that aims to foster collaboration between its eight member agencies. Each symposium focuses on a specific theme, with the most recent event organized around novel therapeutics.